A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
Status:
Completed
Trial end date:
2016-12-22
Target enrollment:
Participant gender:
Summary
This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects
with moderate to severe psoriasis with a PASI score of at least 10. Following run-in,
subjects were randomized and received either oral 30 mg ZPL-3893787 once daily or placebo
once daily for 12 weeks.